Maribavir: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), CHUIKYO (Japan) and CONITEC (Brazil), among others, recommended or restricted maribavir, while AOTMIT (Poland) and TLV (Sweden) did not recommend it.
The record spans 2.2 years, opening at AWMSG (Wales) on 30 Oct 2022 and running to 24 Dec 2024.
PBAC (Australia) changed its position: not recommended in 2023, recommended by 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 14 of 15 records date from 2023 or later.
4 distinct indication wordings are recorded for maribavir by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess maribavir, on 30 Oct 2022; CONITEC (Brazil) did not open a file until 24 Dec 2024 — a moderate spread of 2.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 15 dated records fall in 2023 alone.
PBAC (Australia) is the only agency to have returned to maribavir, recording 2 separate entries.
maribavir has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for maribavir reads 10 recommended, 3 not recommended, 1 restricted and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 24 Dec 2024 | Tratamento de infecção e/ou doença por citomegalovírus que são refratárias (com ou sem resistência a uma ou mais terapia… | incorporated into SUS | source |
| AOTMIT (Poland) | 10 Sep 2024 | programu lekowego „Leczenie pacjentów z niereagującym lub opornym na leczenie zakażeniem wirusem cytomegalii (CMV) (ICD-… | not recommended | source |
| CHUIKYO (Japan) | 15 Aug 2024 | リブテンシティ錠２００ｍｇ | listed on the NHI price list · 52 days after PMDA approval | source |
| PBAC (Australia) | 2024 | Post-transplant cytomegalovirus (CMV) | Recommended | source |
| NYE METODER (Norway) | 11 Feb 2024 | Behandling av cytomegalovirus (CMV)-infeksjon og/eller -sykdom som er refraktær (med eller uten resistens) mot én eller … | introduced | source |
10 further decisions for maribavir, across 10 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 15 decisions for maribavir from 14 agencies, 2022 to 2024. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.